Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a GLP-1 receptor agonist, produces measurable weight loss in clinical trials, with participants losing approximately 10% to 12% of their body weight by 52 weeks at therapeutic doses. Understanding realistic outcomes helps you set achievable goals and make informed treatment decisions. PlexusDx delivers compounded semaglutide from licensed 503A pharmacies to help you reach your personalized weight management targets.
Clinical Trial Data on Semaglutide Weight Loss Outcomes
Randomized controlled trials demonstrate that semaglutide produces dose-dependent weight reduction across diverse patient populations. Participants receiving the highest therapeutic dose experienced average weight loss ranging from 11% to 15% of baseline body weight over one year. Lower starting doses typically result in more modest initial losses of 3% to 7% during the first 3 months, with gradual acceleration as dosing increases.
The STEP trials, which evaluated semaglutide for chronic weight management, enrolled over 4,500 participants across multiple studies. In STEP 1, participants lost an average of 10.2 kg (22.5 lbs) more than placebo recipients, while STEP 2 and STEP 3 showed comparable or greater reductions in body weight. Response variability exists—some individuals achieve 20% or greater weight loss, while others plateau at 5% to 10% reduction, reflecting individual metabolic differences and genetic factors.
Individual Variation in Weight Loss Response to Semaglutide
Not every person loses weight at the same pace or percentage because genetic differences influence how your body responds to GLP-1 therapy. Variants in the GLP1R gene (such as rs6923761), GIPR gene (rs1800437), and metabolic genes like FTO (rs9939609) affect appetite regulation, insulin sensitivity, and energy expenditure. Two people taking identical doses may experience different hunger suppression, satiety duration, and weight loss trajectories based on their genetic makeup.
Environmental factors including diet quality, physical activity level, sleep duration, and stress management significantly modify semaglutide outcomes. Participants who combined medication with structured nutrition programs and regular exercise achieved weight losses at the higher end of clinical trial ranges. PlexusDx offers the Precision Peptide Genetic Test, which analyzes 150+ genetic insights across 49 peptides to identify your individual response patterns and optimize treatment selection from day one.
What to Expect During Your First Year of Semaglutide Treatment
Most people report noticeable appetite reduction and early weight loss within the first 4 weeks of starting semaglutide, though initial results reflect water loss and reduced caloric intake rather than significant fat loss. Weeks 5 through 12 typically show accelerating weight decline as your body adapts and dosing increases—average reductions of 3% to 7% of starting weight are common by the 12-week mark. The plateau phase frequently occurs between months 4 and 8, when weight loss slows or temporarily stalls, reflecting metabolic adaptation and requiring dietary consistency to overcome.
Months 9 through 12 often bring resumed weight loss as your appetite regulation remains suppressed and habits solidify, with cumulative reductions of 10% to 15% evident by the one-year mark for many users. Individual timelines vary considerably—some people reach their goal weight in 6 months, while others require 12 to 18 months. Continuing semaglutide beyond one year typically prevents weight regain, as discontinuation often leads to gradual weight rebound within 6 months.
How PlexusDx Semaglutide Compares to Brand-Name Options
PlexusDx compounded semaglutide injection starts at $149 per month, providing identical active pharmaceutical ingredients as brand-name alternatives at a fraction of the cost, with no insurance required and no membership fees. Compounded medications from licensed 503A pharmacies undergo the same quality and sterility standards as branded products, meeting United States Pharmacopeia (USP) requirements. Your dose may need to go up during treatment. Your price won't—PlexusDx maintains flat monthly pricing across all dose levels, eliminating financial surprises as your treatment progresses.
PlexusDx serves all 50 states and accepts HSA and FSA funds, making premium weight loss therapy accessible regardless of insurance status or prior coverage denials. After completing your first month of treatment, you can add the Precision Peptide Genetic Test ($99 add-on) to discover which genetic variants influence your response to semaglutide and other GLP-1 medications. This genetic insight allows your provider to personalize dosing, medication selection, and lifestyle recommendations based on your individual biology rather than population averages.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How much weight do most people lose in the first month of semaglutide?
Most people lose 2 to 4 pounds in the first month, primarily from reduced fluid retention and decreased caloric intake due to appetite suppression. Significant fat loss becomes more apparent in months 2 through 4 as dosing optimizes and dietary changes compound. Individual results vary based on starting weight, diet adherence, and genetic factors.
Do you keep the weight off after stopping semaglutide?
Clinical evidence shows that weight typically returns within 6 to 12 months after discontinuing semaglutide, as appetite and caloric intake normalize. Sustained weight management usually requires either continuing semaglutide long-term or maintaining significant lifestyle changes achieved during treatment. Genetic factors assessed by PlexusDx Precision Peptide Testing help predict your individual rebound risk and guide decision-making about treatment duration.
Why is PlexusDx semaglutide more affordable than brand-name versions?
PlexusDx sources compounded semaglutide from licensed 503A pharmacies, which eliminates manufacturer markup and marketing costs associated with branded medications. Your dose may need to go up. Your price won't—PlexusDx charges a flat $149/month regardless of dose level. HSA/FSA eligibility and no membership requirements make premium treatment accessible to more patients.
What side effects might I experience on semaglutide?
Common mild side effects include nausea, constipation, and modest appetite suppression, typically occurring in the first 2 to 4 weeks and resolving as your body adjusts. Serious side effects are rare but include severe pancreatitis, thyroid concerns, and gallbladder issues in susceptible individuals. Your PlexusDx provider screens for contraindications during consultation and monitors your response throughout treatment.
How does the Precision Peptide Genetic Test improve my semaglutide results?
PlexusDx Precision Peptide Genetic Testing analyzes variants like GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 to reveal your genetic predispositions for GLP-1 response, metabolic rate, and weight loss potential. This $99 add-on after your first treatment month identifies whether you might benefit more from semaglutide, tirzepatide, or combination therapy. Genetic insights guide personalized dosing and lifestyle recommendations for optimized outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Optimizing Your Health: Can I Take Vitamin D with Ozempic?
Can You Take Zepbound Twice a Week? Understanding the Dosage and Administration